24195-07-1

Usage

Uses

Used in Neurological Research:
Quinolinic acid, 2-methyl ester is used as a biomarker for neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Its potential role in these conditions is being studied to better understand the underlying mechanisms and develop targeted therapeutic interventions.
Used in Drug Development:
Quinolinic acid, 2-methyl ester is being investigated for its potential therapeutic applications in the treatment of neurological disorders. Its activity in the central nervous system and its potential involvement in neuroinflammation and excitotoxicity make it a promising candidate for drug development.
Used in Neuroinflammation and Excitotoxicity Studies:
Quinolinic acid, 2-methyl ester is used in research to explore its potential role in neuroinflammation and excitotoxicity, which are key factors in the progression of various neurological disorders. Understanding its impact on these processes can help in the development of novel therapeutic strategies to mitigate the effects of neuroinflammation and excitotoxicity in the brain.

InChI:InChI=1/C8H7NO4/c1-13-8(12)6-5(7(10)11)3-2-4-9-6/h2-4H,1H3,(H,10,11)

Upstream product

• 67-56-1 methanol 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 124-41-4 sodium methylate 
• 24195-02-6 pyridine-2,3-dicarboxylic acid 3-methyl ester 
• 141-78-6 ethyl acetate 
• 78-92-2 iso-butanol 
• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 

Downstream Products

• 100872-65-9 2-[[(phenylmethyl)amino]carbonyl]-3-pyridinecarboxylic acid 
• 100616-13-5 2-cyclohexylcarbamoyl-nicotinic acid 
• 93-60-7 methyl 3-pyridinecarboxylate 
• 860299-15-6 3-{methyl-[(methyl-phenyl-carbamoyl)-methyl]-carbamoyl}-pyridine-2-carboxylic acid methyl ester 
• 656801-65-9 methyl 3-{[(benzylamino)carbonyl]amino}pyridine-2-carboxylate 
• 656801-67-1 methyl 3-({[(2-phenylethyl)amino]carbonyl}amino)pyridine-2-carboxylate 
• 656801-66-0 methyl 3-({[(4-chlorobenzyl)amino]carbonyl}amino)pyridine-2-carboxylate 
• 656801-71-7 methyl 3-[({[2-(4-fluorophenyl)ethyl]amino}carbonyl)amino]pyridine-2-carboxylate 
• 656801-68-2 methyl 3-[({[2-(4-hydroxyphenyl)ethyl]amino}carbonyl)amino]pyridine-2-carboxylate 
• 5657-51-2 7H-furo[3,4-b]pyridin-5-one 
• 100969-79-7 3-carbomethoxy-2-[(N-benzyl)carbamoyl]pyridine 
• 27507-08-0 3-(4-methoxybenzyl)pyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 1335299-51-8 2-(Azetidine-1-carbonyl)-N-(2-phenyl-imidazo[1,2-a]pyrimidin-7-yl)-nicotinamide 
• 1335299-53-0 3-(2-phenyl-imidazo[1,2-a]pyrimidin-7-ylcarbamoyl)-pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

SYNTHESIS OF A SICKLE CELL DISEASE AGENT AND INTERMEDIATES THEREOF

New processes for preparing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5- yl)pyridin-3-yl)methoxy)benzaldehyde, an agent developed for the treatment of sickle cell disease, and intermediates thereof, are provided herein.

IDO/TDO Inhibitor

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R1 and R2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R1 and R2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R4 represents, for example, —C(═NH)—HN2, and R6 represents, for example, a substituted or unsubstituted aryl group].

Synthesis method of imazapyracid

The invention relates to a synthesis method of imazapyracid, relates to a preparation method of a compound, and in particular, relates to a production and synthesis method of imazapyracid; the methodis characterized by comprising the steps: taking quinolinic acid as a raw material and reacting with acetic anhydride to generate 2,3-pyridine dicarboxylic anhydride; and under a low-temperature condition, continuously reacting with alcohol to generate a compound represented by a structural formula (I), carrying out a ring closing reaction with 2-amino-2,3-dimethylbutyramide under an alkaline condition, extracting to adjust the pH value, and thus obtaining the imazapyracid product. The method has the advantages that a novel method for obtaining imazapyracid is provided, the route reaction speed is high, the product purity is extremely high, the yield is high, the reaction conditions are mild, isomers are avoided, catalysts are not needed, three wastes are few, the synthesis process is extensive, the reaction conditions are optimized, the reaction equipment cost is reduced, generated products are easy to separate, and the production process is simplified.

AZA-A-RING INDENOISOQUINOLINE TOPOISOMERASE I POISONS

The invention described herein pertains to four series of aza-A-ring indenoisoquinolines, which are inhibitors of topoisomerase IB (Top1), and the processes for preparing said aza-A-ring indenoisoquinolines. Also described are methods for treating cancer

Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase i Poisons

Several indenoisoquinolines have shown promise as anticancer agents in clinical trials. Incorporation of a nitrogen atom into the indenoisoquinoline scaffold offers the possibility of favorably modulating ligand-binding site interactions, physicochemical properties, and biological activities. Four series of aza-A-ring indenoisoquinolines were synthesized in which the nitrogen atom was systematically rotated through positions 1, 2, 3, and 4. The resulting compounds were tested to establish the optimal nitrogen position for topoisomerase IB (Top1) enzyme poisoning activity and cytotoxicity to human cancer cells. The 4-aza compounds were the most likely to yield derivatives with high Top1 inhibitory activity. However, the relationship between structure and cytotoxicity was more complicated since the potency was influenced strongly by the side chains on the lactam nitrogen. The most cytotoxic azaindenoisoquinolines 45 and 46 had nitrogen in the 2- or 3-positions and a 3′-dimethylaminopropyl side chain, and they had MGM GI50 values that were slightly better than the corresponding indenoisoquinoline 64.

A practical strategy for the structural diversification of aliphatic scaffolds through the palladium-catalyzed picolinamide-directed remote functionalization of unactivated C(sp3)-H bonds

Hats off to the director: High levels of regio- and stereoselectivity were observed for a broad range of amine substrates with aryl and vinyl iodide coupling partners in the title reaction. The synthetic utility of this strategy was highlighted by the rea

4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES

This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune deseases, inflammatory disorders, multiple sclerosis and other deseases like cancers.

Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin- 2(1H)-one HIV integrase inhibitors

The medicinal chemistry and structure-activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naph

SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS

This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

Efficient access to novel mono- and disubstituted pyrido[3,2-d]pyrimidines

New mono- and disubstituted pyrido[3,2-d]pyrimidines were synthesized starting from the corresponding 2,4-dichloro derivative through SNAr and palladium-catalyzed reactions. SNAr and palladium-catalyzed hydro-deshalogenation occurred